Binghui Li

Dr. Binghui Li

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ZLZhang Lin
Zhang Lin
YHYanhong Hou
Yanhong Hou
BLBinghui Li
Binghui Li
For half a century, digestive endoscopy has advanced under a single dominant paradigm — morphological endoscopy — whose object is the morphological lesion, whose epistemic path is look–classify–confirm by pathology, and whose endpoint is resection of what is seen. That paradigm has delivered enormous value, but the clinical problems now dominating gastroenterology — antimicrobial resistance beyond the reach of empirical therapy and checkpoint-resistant, immunologically “cold” tumors — are problems of interfacial state rather than of form, and they mark the object boundary of a paradigm built on morphology. Meanwhile, the elements of a successor paradigm are already in the endoscopy suite — confocal microscopy, molecular imaging, artificial intelligence, in vivo pathology, same-access resection — yet none has simultaneously changed the object, the epistemic path, and the practical endpoint. We therefore propose interfacial endoscopy as a paradigm of equal standing: within a single endoscopic access, pathogen and immune phenotypes at the mucosal interface are read out in a one-stop manner, and the same access performs targeted in situ intervention — read the interface, classify the phenotype, intervene at once. The paradigm's three-layer structure (ontological, epistemological, praxical) is grounded in two published precursors from our program — the HP-REVISE closed loop for H. pylori pathogen phenotyping and ROSE-mIF immune phenotyping linked to same-access oncolytic intervention — and it stands before a defined five-item validation agenda. If validated, interfacial endoscopy would reposition gastroenterology as an interface-based discipline of in situ precision diagnosis and therapy, elevating the endoscope from the “eyes” of the field to its “eyes, readout, and hand”.

9 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ZLZhang Lin
Zhang Lin
YHYanhong Hou
Yanhong Hou
BLBinghui Li
Binghui Li
KWKai Wu
Kai Wu
Despite four decades of therapeutic progress, Helicobacter pylori eradication continues to decline in high-resistance regions, where clarithromycin resistance exceeds the 15% threshold that renders empirical therapy unreliable. Maastricht VI and the 2024 American College of Gastroenterology guideline mandate susceptibility-directed therapy wherever predicted efficacy falls below 80%, yet no existing method delivers phenotypic susceptibility results within the endoscopy encounter: culture requires 5–7 days and succeeds in roughly half of biopsies, while molecular assays interrogate only known mutations and cannot assess bacterial viability. The result is a persistent “open loop” of biopsy, delayed reporting, empirical therapy, and recurrent failure. Fluorescence rapid on-site evaluation (F-ROSE) can close this loop. In published cohorts, dual-fluorescence viability staining visualized viable organisms—including viable but non-culturable coccoid forms—within 25–30 minutes, with a sensitivity of 0.947 in a 317-patient comparison. A peer-reviewed proof-of-concept study showed that the fluorescence residual rate after 1 hour of antibiotic exposure provides a culture-free phenotypic susceptibility readout directly from biopsies, with 100% sensitivity for amoxicillin and levofloxacin. Combined with same-visit tailored therapy and a structured training program that raised interpretation accuracy from 58.1% to 86.8%, these steps form an integrated paradigm we designate HP-REVISE (H. pylori real-time evaluation by visual imaging and phenotypic susceptibility estimation): SEE, TEST, TREAT, TEACH—all at the endoscope tip. Here we set out the rationale, the published evidence, the unresolved biological and standardization questions, and the registered multicentre trial that will determine whether the loop improves eradication at scale.